Synthetic Biologics has raised $12m through the private placement of 120,000 series A preferred shares priced at $100 a share.

The US-based biotechnology company plans to use the funds for general corporate purposes.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

German pharmaceutical company Bayer has signed a five-year research agreement with healthcare service provider Vanderbilt University Medical Center to develop therapies targeting kidney diseases.

HitGen and Takeda Pharmaceutical have signed an agreement, under which the former will use its advanced DNA-encoded technology to discover innovative small molecule leads and license them exclusively to Takeda.

HitGen is Chinese biotechnology company, while Takeda is a Japanese pharmaceutical company.

"German pharmaceutical company Bayer has signed a five-year research agreement with healthcare service provider Vanderbilt University Medical Center to develop therapies targeting kidney diseases."

Amylon Therapeutics has secured seed funding from a group of institutional and private investors.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The Netherlands-based company is focused on the development of central nervous system (CNS) therapies and plans to use the funds towards the progress of its lead candidate AT-010 targeting Katwijk’s disease.

Canadian monoclonal antibody therapies developer AbCellera Biologics and UK-based pharmaceutical company GlaxoSmithKline (GSK) have signed a research agreement for the discovery of monoclonal antibodies.

AbCellera Biologics will use its single-cell antibody screening platform to discover antibodies targeting undisclosed membrane protein, while GSK will develop therapeutics based on the discovered antibodies, as part of the agreement.